Skip to main content
. 2020 Aug 14;12(8):2279. doi: 10.3390/cancers12082279

Figure 1.

Figure 1

Assessment of syndecan-1 peptide (SDC1-Lip) uptake in cells using flow cytometry. S2VP10, S2CP9, and Miapaca2 cells treated with SDC1-Lip compared to untargeted liposome IR780; control S2VP10 = 63.7% (p = 0.00002), S2CP9 = 47.3% (p = 0.00021), and Miapaca2 = 18.6% (p = 0.01994). MCF-7 (negative control) cells treated with SDC1-Lip IR780 had 5.7% uptake (p = 0.37331).